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ABSTRACT
Objective To prospectively explore the following patient-
reported outcome measures (PROMs) in the management 
of neovascular age-related macular degeneration (nAMD): 
(1) self-reported visual function, (2) symptom-state, (3) 
general-health and (4) satisfaction of treatment.
Methods and analysis Corresponding to the 
four PROMs, participants responded to the following 
questionnaires: (1) National Eye Institute Visual-
Functioning-Questionnaire (NEI-VFQ-25), (2) Patient-
Acceptable-Symptom-Status (PASS 5), (3) EuroQol-
Group-Questionnaire (EQ-5D-3L) and (4) Dimensions 
of Importance in Treatment of nAMD (DITAMD). Data 
were collected at baseline and after 3, 6 and 12 months 
of intravitreal antivascular endothelial growth factor 
treatment. Results were evaluated with t-tests and mixed 
linear regression analyses.
Results The study included 197 patients. At baseline 
NEI-VFQ-25 (79.53±14.52) and EQ-5D (0.74±0.28) 
had relatively high scores, whereas PASS 5 was below 
‘acceptable’ (3.30±0.80). At 12 months NEI-VFQ-25 and 
PASS 5 showed significant improvement, whereas EQ-5D 
and DITAMD remained unchanged. At baseline patients 
receiving treatment of the better-seeing eye (BSE) (n=52) 
reported significantly worse NEI-VFQ-25 and PASS 5 than 
patients for whom treatment only involved the worse-
seeing eye (WSE), (n=145). In contrast to BSE patients, 
there was no improvement of NEI-VFQ-25 for WSE patients 
at 12 months, despite a significant improvement in best-
corrected visual acuity (BCVA). Two independent variables, 
treatment including the BSE and BCVA for the treated eye, 
were found to predict both NEI-VFQ-25 and PASS 5.
Conclusion After 12 months of nAMD treatment, there 
was a significant improvement in PASS 5 and NEI-VFQ-25, 
the latter depending on whether therapy included BSE. 
EQ-5D and DITAMD remained unaltered.
InTROduCTIOn
Age-related macular degeneration (AMD) is 
a common cause of vision loss in the elderly 
and poses an increasing global health chal-
lenge due to an ageing population.1–4 AMD 
can be divided into the atrophic type and the 
more aggressive neovascular type (nAMD). 
nAMD develops in 10%–15% of patients, but 
it accounts for more than 80% of legally blind 
cases and can have a devastating effect on 
vision-related quality of life.5 6 The introduc-
tion of intravitreal antivascular endothelial 
growth factor (anti-VEGF) treatment has 
resulted in a paradigm shift in the manage-
ment and prognosis of nAMD.7–10 Still, there 
are important limitations associated with such 
therapy. Although nAMD is a chronic disease, 
the aim of anti-VEGF treatment is not to cure 
patients, but merely to suppress the disease’s 
neovascular activity. In consequence many 
years of repetitive intravitreal injections, as 
Significance of the study
What is already known about this subject?
 ► Patient-reported outcome measures (PROMs) are 
increasingly emphasised in clinical research as a 
crucial part of neovascular age-related macular 
degeneration (nAMD) management. Yet, few studies 
on nAMD treatment define PROMs as the primary 
outcome.
What are the new findings?
 ► The present study explored the performances of four 
different PROMs questionnaires in the assessment 
of nAMD patients during their first year of antivas-
cular endothelial growth factor treatment. At base-
line two of the PROMs questionnaires, self-reported 
visual function and general health, had relatively 
high scores, whereas visual symptom-state was un-
der ‘acceptable’. Both self-reported visual function 
and symptom-state significantly improved during 
12 months follow-up, with treatment including bet-
ter-seeing eye and best-corrected visual acuity of 
the treated eye as main predictors.
How might these results change the focus of 
research or clinical practice?
 ► Utilising appropriate PROMs tools in a multimodal 
approach to the management of nAMD could in-
crease the understanding of how the disease and 
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well as clinical assessments to monitor response, may be 
necessary.11–13
The chronicity and invasiveness of anti-VEGF therapy 
makes it crucial to correlate treatment effects in terms 
of visual and anatomical changes to self-reported visual 
function and the patient’s own treatment experience.14–19 
Such patient-reported outcome measures (PROMs) are 
emphasised in both clinical research and practice, and 
they are crucial in the evaluation of nAMD treatment.20–22 
PROMs appraises the patient’s perspective of the disease, 
subjective treatment outcome and self-reported visual 
function.14 18 Various ophthalmic PROMs have been 
developed and studied among AMD patients,14 18 yet 
only a small proportion of studies on nAMD treatment 
include PROMs as primary outcome.23 In everyday clin-
ical practice little attention is also paid to the correlation 
between visual acuity and disability as well as patient’s 
own treatment experience.6 24 Utilising several PROMs 
tools in a multimodal approach to the management of 
nAMD might increase the understanding of how the 
disease and its treatment affect patients.
Preserving visual function in daily life is a vital treat-
ment goal for nAMD patients.16–18 From the clinician’s 
perspective functional outcome in terms of best-corrected 
visual acuity (BCVA) is typically evaluated monocularly, 
and most definitions of visual impairment focus on the 
status of the better-seeing eye (BSE). However, patients 
respond to PROMs based on their binocular vision, and 
it is challenging to assess how much each eye contributes 
to the self-reported visual function.25 Especially for eye 
diseases affecting the central vision (eg, AMD), there 
are conflicting data regarding the relationship between 
BCVA of the worse-seeing eye (WSE) and self-reported 
visual function.26 The choice of PROM instrument is also 
of importance in capturing the influence of the BSE or 
WSE.25
The aim of the present study was to prospectively 
explore how newly diagnosed nAMD patients responded 
to four different PROMs that focus on self-reported visual 
function, general health, acceptable visual symptom-state 
and satisfaction of anti-VEGF treatment during 12 
months of follow-up. Furthermore, we wanted to explore 
which factors influence these PROMs instruments and to 
compare the responses of patients for whom treatment 
included BSE with the responses of patients that only 
received treatment of the WSE.
MATeRIAlS And MeTHOdS
The study included treatment-naïve nAMD patients 
scheduled to initiate intravitreal anti-VEGF therapy 
at the Department of Ophthalmology, Oslo Univer-
sity Hospital, Norway. The inclusion period was from 
February 2015 to March 2017. Inclusion criteria were 
Scandinavian-speaking patients without known cognitive 
impairment that were scheduled for intravitreal treat-
ment. Treatment was in accordance with the department’s 
clinical practice; bevacizumab (Avastin; Roche, Basel, Swit-
zerland) was the first-line drug, while treatment-resistant 
eyes defined as those with the inability to achieve full 
resolution of macular fluid despite monthly bevacizumab 
injections, were converted to aflibercept (Eylea; Bayer, 
Leverkusen, Germany). Injection intervals were individu-
alised by means of a treat and extend (T&E) algorithm27; 
if a dry macula was achieved, the treatment frequency was 
extended at 2-week intervals until a 12-week interval was 
reached or macular fluid reoccurred on optical coher-
ence tomography. Researchers that were not involved in 
the diagnostic or therapeutic intervention carried out 
the recruitment procedure and data collection.
data collection
Patients responded to PROMs at baseline and at 3, 6 
and 12 months (with the exception of the questionnaire 
measuring satisfaction of treatment, for which baseline 
was not applicable). At baseline the data collection took 
place as a face-to-face interview in the department’s 
outpatient clinic at the time of diagnoses and indication 
for treatment (prior to first injection), while telephone 
interviews were conducted for the follow-up evaluations. 
The following four PROMs were used:
I. The National Eye Institute Visual Functioning 
Questionnaire-25 (NEI-VFQ-25) is a vision-specific 
inquiry.28 It contains 25 questions on visual function 
in daily life, is sensitive to changes in visual acuity and 
commonly used in AMD studies as well as proven to 
correlate with visual acuity in treatment of nAMD.29 
The score ranges from 0 to 100; 0 designates worst 
state and 100 designates no disability related to vi-
sual function. NEI-VFQ-25 has 12 subcategories: (1) 
general health; (2) general vision; (3) ocular pain; 
(4) near vision; (5) distance vision; (6) social func-
tioning; (7) mental health; (8) role difficulties; (9) 
dependency; (10) driving; (11) colour vision; (12) 
peripheral vision.
II. Dimensions of Importance in Treatment of neovas-
cular Age-related Macular Degeneration (DITAMD) 
is a questionnaire measuring the satisfaction of im-
portant dimensions during intravitreal injection 
treatment.30 DITAMD contains 15 dimensions: (1) 
receive treatment to preserve vision; (2) informa-
tion about your diagnosis and treatment; (3) wait-
ing time at the clinic; (4) trust in those treating you; 
(5) accommodating staff; (6) follow-up structure; 
(7) planning of treatment consultations; (8) treat-
ment continuity; (9) good pain relief during injec-
tion treatment; (10) injection technique to reduce 
discomfort during treatment; (11) transport/travel 
challenges back and forth from the eye clinic; (12) 
good hygiene during treatment; (13) receive early 
access to treatment after referral; (14) involvement 
in treatment decisions; (15) information about pos-
sible visual aids. DITAMD has a weighted algorithm 
to calculate the total score, which implies the rela-
tive importance among the dimensions. The score 
ranges from 1 to 5; 5 designates ‘best managed’ and 
1 designates ‘not at all managed’.
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Table 1 Baseline characteristics. All patients and patients divided in two subgroups: (1) treatment included the better seeing-
eye (BSE) defined by best corrected visual acuity (BCVA) (the subgroup also contained patients receiving bilateral treatment) 
and (2) patients for which treatment only included the worse-seeing eye (WSE)
Parameters All patients (n=197)
Patients with BSE 
treated (n=52)
Patients with WSE 
treated (n=145)
BSE vs WSE 
treated (P value)
















NEI-VFQ25 79.53±14.52 71.25±16.50 82.48±12.56 <0.001**
PASS 3.30±0.80 3.60±0.66 3.20±0.82 0.002**
EQ-5D 0.74±0.28 0.68±0.32 0.76±0.26 0.085
Bold denotes significant change from baseline: **p<0.001 and *p<0.05. Mean value (SD).
EQ-5D, EuroQol Group Questionnaire; NEI-VFQ-25, National Eye Institute Visual-Functioning-Questionnaire-25.
III. Patient Acceptable Symptom Status (PASS 5) con-
tains a simple question measuring the patient’s 
symptom state. In the current study the question 
specifically regarded visual symptoms during the last 
month. The score ranges from 1 to 5; 5 designates 
‘very bad’ and 1 designates ‘very good’.31
IV. The EuroQol Group Questionnaire (EQ-5D-3L) 
evaluates the patient’s self-rated health. EQ-5D-3L 
contains five questions: (1) mobility; (2) self-care; 
(3) usual activities; (4) pain/discomfort; (5) anxi-
ety/depression with three response options. The to-
tal score ranges from 0 to 1; 0 designates ‘dead’ and 
1 designates ‘perfect health’.32
In addition, the following clinical data were collected 
from the patients’ medical records: BCVA for each eye, 
choice of anti-VEGF medication, and number of injec-
tions received in 12 months. BCVA was obtained from a 
ClearChart (Reichert Technologies, Depew, New York, 
USA) digital acuity test that displayed letter optotypes and 
logarithm of the minimal angle of resolution (logMAR) 
line size progression.
Patient and public involvement
Two patient research partners with known neovascular 
AMD (nAMD) were involved in the planning of the study. 
They gave comments and advice regarding study informa-
tion and questionnaires. One of the four questionnaires 
used in the study, DITAMD, was developed in partnership 
with nAMD patients.30 Patients that responded to the 
questionnaires in current study also gave their opinion 
on the relevance of each questionnaire. Finally, prelim-
inary study results have been presented for patients and 
their relatives as part of the clinic’s patient education 
programme.
Statistical analyses
Paired sample t-tests were used to examine changes 
in PROMs and BCVA from baseline to 12 months; for 
NEI-VFQ-25 the analyses included its subscores. In 
order to relate PROMs to treatment of either the BSE 
or WSE, we defined two patient subgroups: (1) patients 
for whom anti-VEGF treatment included the BSE, as 
defined by BCVA (the subgroup also contained patients 
receiving bilateral treatment) and (2) patients for 
whom treatment only included the WSE. Independent 
sample t-tests were used to compare the BSE and WSE 
subgroups.
Regression analyses with mixed linear models were 
used to examine the influence of independent vari-
ables on PROMs during follow-up. We also performed 
subscore analysis of NEI-VFQ-25 ‘near vision’, since 
this subscore is strongly associated with central vision. 
The independent variables included in the regression 
analyses were: age, gender, number of injections, BCVA 
for the treated eye, BSE treated (yes/no) and bilateral 
treatment (yes/no). Statistical significance was defined 
as p<0.05. Data are presented as mean (±SD). Mixed 
models were performed using R (V.3.4.1) and the 
package lme4, all other analyses were performed using 
SPSS Statistics V.25.
ReSulTS
Of 203 naïve nAMD patients screened for participation, 
197 were included in the study. Three patients declined 
and another three did not meet the inclusion criteria. 
Mean (SD) age was 83.4 (7.6) years and 140 (71%) were 
females. The mean BCVA was 0.59 (±0.51) logMAR for 
the treated eye and 0.19 (±0.26) logMAR for the best eye 
(table 1).
Baseline PROMs
The baseline PROMs values were generally high; mean 
NEI-VFQ-25 patient-reported visual function was 79.53 
(±14.52) out of 100 and mean EQ-5D was 0.74 (±0.28) 
out of 1.0. In contrast, the baseline PASS 5 score was of 
3.30±0.80 out of 5 (table 1).
The BSE subgroup (n=52) had a better mean baseline 
BCVA for the treated eye than the WSE subgroup (n=145) 
(table 1), and it reported significantly worse NEI-VFQ-25 
and PASS 5 scores. There was no significant difference in 
baseline EQ-5D between the subgroups, but there was a 
trend towards lower values in the BSE subgroup.
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Table 2 Paired sample t-test analyses showing the change in patient reported outcome measures (PROMs) and best 
corrected visual acuity (BCVA) measured during 12 months follow-up for all patients and for the subgroups where treatment 
included better seeing-eye and patients for which treatment only included the worse-seeing eye
All patients treated eye Patients with best seeing eye treated Patients with worst seeing eye treated
B 3 m 6 m 12 m B 3 m 6 m 12 m B 3 m 6 m 12 m


























NEI-VFQ-25 79.7 82.2** 82.6** 82.1* 71.0 76.9** 76.4** 76.1* 83.0 84.2 84.9 84.4
PASS 5 3.3 2.8** 2.7** 2.8** 3.6 2.9** 2.9** 3.0** 3.2 2.8** 2.6** 2.7**
EQ-5D 0.74 0.73 0.76 0.77 0.68 0.69 0.73 0.74 0.77 0.74 0.77 0.78
DITAMD management NA 8.3 8.4 7.9 NA 8.2 8.4 7.9 NA 8.3 8.4 7.9
Bold denotes significant change from baseline: **p < 0.001 and *p < 0.05.
B, baseline;DITAMD, Dimensions of Importance in Treatment of neovascular Age-related Macular Degeneration; EQ-5D, EuroQol Group 
Questionnaire; 6m, 6 months;12m, 12 months; 3 m, 3 months;NA, Not applicable; NEI-VFQ-25, National Eye Institute Visual-Functioning-
Questionnaire-25.
Figure 1 Relationship between self-reported visual function (NEI-VFQ-25) and best corrected visual acuity in logMAR of 
the treated eye during 12 months of antivascular endothelial growth factor therapy for all patients in the study. NEI-VFQ-25, 
National Eye Institute Visual-Functioning-Questionnaire-25.
Improvement of PROMs compared to BCVA during 12 months 
of treatment
During the 12 months follow-up, patients received a 
mean of 9.2 (±2.9) injections. The proportion of treat-
ment resistant eyes that were converted to aflibercept was 
8% at 3 months, 25% at 6 months and 48% at 12 months. 
There were no significant differences between the BSE 
and WSE subgroups for neither mean number of injec-
tions nor proportion of treatment resistant eyes converted 
to aflibercept (data not shown). The main reasons for 
discontinuing treatment at 12 months were permanent 
loss of BCVA (n=26), death (n=3) and personal choice 
(n=2). At 12 months 168 of 197 patients responded to the 
PROMs questionnaires.
There was a significant improvement in both BCVA 
(p<0.001) and NEI-VFQ-25 patient-reported visual func-
tion (p<0.05) at 12 months compared with baseline 
(table 2, figure 1). There was also a significant improve-
ment in PASS 5 at 12 months compared with baseline, 
from ‘under acceptable’ (3.3) to ‘over acceptable’ 
(2.8). There were no significant changes in EQ-5D and 
DITAMD management scores (table 2).
For the WSE subgroup there was no significant change 
in patient-reported visual function, despite a signifi-
cant improvement in BCVA at all time-points (p<0.001) 
(table 2, figure 2, online supplementary table 1). The 
BSE subgroup only displayed a significant improvement 
in BCVA at 6 months (p<0.05) (table 2). Nevertheless, 
there was significant improvement in patient-reported 
visual function from baseline to both 3, 6 and 12 months 
(table 2; figure 3). Both WSE and BSE subgroups had a 
significant improvement in PASS 5 from baseline to 12 
months, and both groups reported an ‘over acceptable’ 
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Figure 2 Change in self-reported visual function (NEI-VFQ-25) and best corrected visual acuity (BCVA) in logMAR of the 
treated eye during 12 months of follow-up for the subgroup where treatment only included the worse-seeing eye. The solid 
line represents NEI-VFQ-25, whereas the dotted line represents logMAR BCVA of the treated eye. NEI-VFQ-25, National Eye 
Institute Visual-Functioning-Questionnaire-25.
Figure 3 Change in self-reported visual function (NEI-VFQ-25) and best corrected visual acuity (BCVA) in logMAR of treated 
eye during 12 months of follow-up for the subgroup where treatment included better seeing-eye. The solid line represents 
NEI-VFQ 25, whereas the dotted line represents logMAR BCVA of the treated eye. NEI-VFQ 25, National Eye Institute Visual-
Functioning-Questionnaire-25.
state at 12 months (table 2). EQ-5 and DITAMD only 
displayed small, non-significant changes.
Paired sample t-tests of NEI-VFQ-25 sub-scores showed 
a significant improvement after 12 months of treatment 
for the following sub-scores: “general vision”, “near 
vision”, and “mental health” (table 3). Analyses also 
showed a significant decrease in the sub-scores “general 
health” and “colour vision” (table 3).
Variables predicting PROMs during 12 months of treatment
Mixed linear regression analyses showed that among 
factors predicting PROMs response during the 12 months 
P
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Table 3 Paired sample t-test analyses showing the change 
in points of NEI-VFQ-25 sub-scores from baseline to 12 
months of antivascular endothelial growth factor treatment
NEI-VFQ-25 subscores
Change in points from 
baseline to 12 months 
(CI) P value
General health −4.0 (−7.6 to −0.4) 0.029
General vision 6.1 (3.2 to 9.0) 0.000
Ocular pain 0.7 (−3.0 to 4.4) 0.692
Near vision 3.3 (0.3 to 6.3) 0.033
Distance vision 0.8 (−2.6 to 4.2) 0.642
Social function 0.9 (−1.9 to 3.7) 0.535
Mental health 5.8 (3.6 to 8.0) 0.000
Role difficulties 3.9 (−0.2 to 8.1) 0.061
Dependency −1.2 (−3.7 to 1.2) 0.322
Driving 0.4 (−5.2 to 5.9) 0.898
Colour vision −3.6 (−6.1 to −1.0) 0.007
Peripheral vision −0.6 (−3.1 to 1.9) 0.643
Bold denotes significant values: **p<0.001 and *p<0.05.
NEI-VFQ 25, National Eye Institute Visual-Functioning-
Questionnaire-25.
follow-up, both treatment including the BSE and BCVA 
of the treated eye were predictors of both self-reported 
visual function in general and its sub-score ‘near-vision’, 
as well as the visual symptom-state (online supplemen-
tary tables 2 and 4). We also found that gender predicted 
general health where; on average, men reported better 
health than women (online supplementary table 3). In 
addition, people who were treated on both eyes had 
higher general health. Furthermore, both age and 
follow-up time were found to predict satisfaction of treat-
ment (online supplementary table 5). Finally, patients 
with higher treatment intensity had visual symptom-state 
improved; however, this effect decreased during the study 
period (online supplementary table 4).
dISCuSSIOn
The present study investigated how nAMD patients 
responded to four different PROMs during the first year of 
intravitreal anti-VEGF treatment. At baseline both self-re-
ported visual function and general health values were 
high, whereas acceptable visual symptom-state was below 
‘acceptable’. During 12 months of treatment, both symp-
tom-state and self-reported visual function significantly 
improved, whereas general health and satisfaction of treat-
ment remained unchanged. Interestingly, the patients that 
only received treatment of the WSE did not experience the 
same improvement in self-reported visual function as the 
patients for whom treatment included the BSE.
Patient demographics, general health-state, and the 
time from diagnosis to treatment may affect baseline 
self-reported visual function. The study setting was a 
large university clinic in a country with a universal public 
health system; national guidelines set a limit of 6 weeks 
from time of referral to initiation of nAMD treatment. 
We found that the overall NEI-VFQ-25 scores (79.5) were 
slightly higher than reported in the pivotal MARINA 
(69.3) and ANCHOR (69.9) nAMD trials, but some-
what lower than a recently published Swiss real-life study 
(86.5).29 33 Our patient population also had a higher 
mean age (83.4 years) than the respective studies (mean 
77.1, 77.0 and 76.7 years).
Following initiation of intravitreal anti-VEGF treat-
ment, nAMD patients will typically experience an initial 
improvement in BCVA before plateauing. The goal of 
anti-VEGF treatment in nAMD is principally a long-term 
stabilisation of neovascular disease and prevention of 
rapid vision loss.8 10 The present study found significant 
improvement in both BCVA and self-reported visual func-
tion at 12 months. In addition, BCVA of treated eye was 
found to be a predictor for self-reported visual function 
as well as visual symptom-state, confirming the associa-
tion between the objective and subjective visual function 
and their mutual response to anti-VEGF treatment.29
Previous research suggests that a clinically mean-
ingful change in PROMs varies by both population 
and context.34 A study of nAMD patients performed 
by Suñer and colleagues indicates that a 4-points to 
6-points change in NEI VFQ-25 score, corresponding to 
a 15-letter change in BCVA, represents a minimal clini-
cally important difference (MCID).29 In the present study 
the mean improvement in NEI-VFQ-25 at 12 months was 
2.4 points, and only two NEI-VFQ-25 sub-scores (‘general 
vision’ and ‘mental health’) displayed a MCID of at least 
four points. Yet, for the BSE subgroup the mean overall 
improvement was 5.1 points at 12 months. Despite the 
absence of concurring improvement in BCVA, this 
satisfies the definition of a MCID in self-reported visual 
function. Notwithstanding an improvement in BCVA 
of more than 15 letters at 12 months, patients that only 
received treatment of the WSE did not experience a 
similar improvement in self-reported visual function. 
Treatment including BSE was also found to be a predictor 
for self-reported visual function in general, the subscore 
‘near-vision’, as well as visual symptom-state during 12 
months of treatment. These findings support the notion 
that treatment including the BSE more profoundly 
affects the self-reported visual function.23 In the present 
study a ceiling effect due to higher baseline PROMs 
scores for the WSE subgroup may have confined the 
potential for PROMs improvement. By contrast, previous 
studies have shown a correlation between self-reported 
quality of life and BCVA, regardless of treatment of WSE 
or BSE.25 26 For instance, in the MARINA and ANCHOR 
trials, NEI-VFQ-25 improved in both the BSE and WSE 
subgroup. Nevertheless, the improvement in the WSE 
subgroup was only modest (2.6 points at 24 months) and 
did not satisfy the definition of a MCID.26
A clinical dilemma arises from the fact that patients 
whose WSE is being treated fail to report a clinically 
meaningful improvement in PROM. The finding raises 
the question as to which extent anti-VEGF treatment is 
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of value in the perspective of a WSE patient. Still, we do 
not believe that lack of PROM improvement represents 
an argument against WSE treatment. Instead, it under-
scores the importance of proper counselling of nAMD 
patients; an individual whose WSE is being treated should 
be informed that AMD inevitably contains a risk of bilat-
eral neovascular involvement. In the event of visual loss 
in the second eye, the value of WSE treatment becomes 
apparent. Ultimately, disseminating PROMs knowledge 
in the follow-up of nAMD patients could help tailor 
counselling and treatment in line with individual expec-
tations, thereby promoting a patient-cantered care.
There was also a significant improvement in PASS 5 
from baseline to 12 months, corresponding to a visual 
symptom state improvement from ‘under acceptable’ to 
‘over acceptable’. Accordingly, PASS 5, which composes 
only a single question about visual symptoms, can be 
used as a quantitative measurement of the patient-re-
ported treatment effect. Beyond the NEI-VFQ-25 and 
PASS 5 questionnaires, a significant change in PROMs 
was not found. The observation adds to the evidence that 
EQ-5D, a generic PROM, is less sensitive to changes in 
visual function.35 Similar findings were recently reported 
in a glaucoma study.36 The lack of change in DITAMD 
management total score may indicate that this PROM 
merely points to patients’ experience with specific treat-
ment dimensions and how they are managed, rather than 
recognising overall treatment alterations.30
The study has some important limitations. The number 
of patients in the BSE subgroup was smaller than in the 
WSE group, challenging the comparison between the two 
subgroups. Still, the two subgroups had similar age and 
gender distributions, as well as similar number of injections 
and drug of choice. Furthermore, the current definition 
of BSE and WSE was only based on the BCVA and did not 
include a cut-off limit, as others have suggested.26 Still, if a 
limit were to be defined as at least five letters,26 90.8% of 
the patients in our study would have had a clinical relevant 
difference in BCVA between the eyes.
In conclusion, among four different questionnaires 
evaluating patient-reported outcomes during 12 months 
of anti-VEGF treatment of nAMD, there was a signifi-
cant improvement in PASS 5 and NEI-VFQ 25 scores, 
the latter being highly dependent on whether treatment 
included the BSE. The two remaining questionnaires, 
EQ-5D and DITAMD management did not display signif-
icant changes despite treatment.
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